CURRICULUM VITAE

DAVID C. RAGAN, M.D.

2777 Mile High Circle Drive, Denver, CO 80211 • 303-825-8822 (office) • 303-825-4022 (fax)

PROFESSIONAL EXPERIENCE

The Urology Center of Colorado (TUCC), Denver, CO Dec 2006 – Present

Director of Advanced Therapeutics Clinic (ATC) for Prostate Cancer

- Diagnose and treat advanced prostate cancer with androgen deprivation therapy, oral novel hormonal therapies, including androgen-receptor signaling inhibitors, PARP inhibitors, and immunotherapy as well as working in collaboration with medical and radiation oncologists to offer radiopharmaceutical and chemotherapy treatments to a current patient population of 250+ patients.
- Offer Phase 1-3 clinical trials to expand therapeutic options for complex oncological patients in an on-site research department.
- Provide surgical interventions for this patient group at TUCC's on-site ambulatory surgery center and area community hospitals.
- Lead CME-accredited monthly ATC tumor board with a multidisciplinary team of urologists, medical oncologists, radiation oncologists, radiologist, ATC nurse, patient navigator, and pharmacy technician.
- Supervise pharmacy technician and in-office dispensing (IOD) of medication in ATC.

General Urologist

- Provide group call coverage to three community-based hospitals: Lutheran Medical Center, 338-bed, acute care, Level-II trauma center; St. Joseph Hospital, 400-bed, acute care hospital; Presbyterian/St. Luke's Medical Center, 680-bed, acute care hospital with the Colorado Blood Cancer Institute, the largest blood and marrow transplant center in the state.
- Maintain general urology practice of 1,500+ patients that provides comprehensive care, including in-house radiology services, laboratory, pathology, and ambulatory surgery center with four operating rooms.
- Deliver high-quality, comprehensive urological care as a member of a 29 physician and advanced practice provider team, located at three TUCC locations.
- Offer telehealth clinic appointments, as-needed-basis, through Doximity platform.
- Served as Chair of Surgery Department at Lutheran Medical Center, July 2009 - June 2010.

Rocky Mountain Regional Affairs Medical Center, Aurora, CO May 2015 – Present

Assistant Clinical Professor for Surgery-Urology Department

- Work a 0.25 FTE physician position in the urology clinic at Veterans Administration (VA) Hospital to increase patient access to urological care.
- Supervise physician assistants and University of Colorado School of Medicine urology residents in a fully accredited ACGME 5-year residency program during clinical rotations to teach latest advances in urological care and up-to-date recommendations for the treatment of urological diseases.
- Participated in Urology Grand Rounds virtually with the University of Colorado Division of Urology and General Surgery during the Federal COVID-19 Public Health Emergency.
- Provided telehealth clinic appointments via VA Video Connect during the Federal COVID-19 Public Health Emergency.

Western Urologic Associates, Wheat Ridge, CO July 2003 – Dec 2006

General Urologist

- Provided comprehensive urological care as part of an eight member physician team with collaborative community partnerships for radiology, laboratory, and surgery services.
- Upheld an active clinical and surgical practice for patients within a community hospital network that included Lutheran Medical Center; St. Anthony's Central Hospital, a Level I trauma center; St. Anthony's North Hospital; and North Suburban Medical Center.
- Worked with a physician team to provide 24-hour/7 days/week on-call service for emergent, urgent, and general rounds at community hospitals.

USAF - Evans Army Community Hospital, Fort Carson, CO July 1999 – June 2003
USAF - United States Air Force Academy Hospital, USAF Academy, CO
General Urologist

- Provided general adult and pediatric urologic care to 64,000 active duty military members, dependents, and retirees in the Pikes Peak region at Evans Army Community Hospital.
- Acted as preceptor of physician assistant student rotating for two weeks in urology.
- Worked in the Air Force Academy Hospital urology clinic on a rotating basis to provide comprehensive urologic care for the USAF Academy community.
- Maintained on-call services as part of a four physician team based at Evans Army Hospital.
- Major in the United States Air Force, active duty.

EDUCATION

Indiana University School of Medicine Department of Urology, Indianapolis, IN July 1995 - June 1999
Urology Residency Training Program

- Completed four month urology rotations as a junior and chief resident at five area hospitals: Indiana University Hospital, Riley Children's Hospital, VA Hospital, Wishard Memorial Hospital (county), and Methodist Hospital (private).
- Publications: Journal of Urology, 1999
- Presentations: AUA, 1998; Kimbrough Urological Seminars, 1998, 1997; AUA North Central Section, 1996
- Other research presented: ASCO, 1999; AUA 1998
- Captain in the United States Air Force Reserve.

Indiana University School of Medicine Department of Urology, Indianapolis, IN July 1993 - June 1995
General Surgery Intern Training Program

- Completed 2-4 month rotations in general surgery, vascular surgery, transplant, cardiovascular surgery, trauma, emergency medicine, and pediatric surgery at four area hospitals.
- Awards: Golden Scalpel Award for Best Surgical Intern, 1993-1994
- Captain in the United States Air Force Reserve.

Case Western University School of Medicine, Cleveland, OH June 1993
Doctor of Medicine (M.D.)

- Dean's List 1989 - 1993
- Second Lieutenant in the United States Air Force Reserve.

University of Notre Dame, Notre Dame, IN May 1989
B.S. in Pre-Professional Studies

- Dean's List 1985-1989
- Graduated with distinction: Magna Cum Laude
- Emergency Medical Technician Certification

ACTIVE CERTIFICATIONS & LICENSURE

Diplomate of The American Board of Urology	2001 - Present
Colorado Medical License	1999 - Present
Drug Enforcement Agency License	2003 - Present
Basic Life Support	Expires May 2024

PROFESSIONAL AFFILIATIONS

The American Urological Association (AUA) member	1993 - Present
South Central Section of the AUA member	1999 - Present
Rocky Mountain Urological Society member	2003 - Present
Rocky Mountain Urological Society Board member	April 2018 - March 2022

PUBLICATIONS

Ragan, D. C., Casale, A. J., Rink, R. C., Cain, M. P. and Weaver, D. D.: Genitourinary Anomalies in the CHARGE Association. J. Urology, **161:** Feb 1999

PRESENTATIONS

Recurrences in Nonseminomatous Germ Cell Tumors after Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PCRPLND). David C. Ragan, M.D.; Richard S. Foster, M.D.; Craig R. Nichols, M.D.; John P. Donohue, M.D.; Indiana University, Indianapolis, IN.
Presented at the AUA 93rd Annual Meeting, May 1998
Presented at the 46th Annual Kimbrough Urological Seminar, October 1998

Genitourinary Anomalies in the CHARGE Association. David C. Ragan, M.D., Richard C. Rink, M.D., Anthony Casale, M.D., Mark P. Cain, M.D., and David D. Weaver, M.D.; Indiana University Medical Center, Indianapolis, Indiana.
Presented at the 45th Annual Kimbrough Urological Seminar, November 1997

Increased incidence of renal anomalies, other than agenesis, in infertile men with congenital absence of the vas deferens (CAVD). David C. Ragan, M.D. and Samuel T. Thompson, M.D.; Methodist Hospital, Indianapolis, Indiana.
Presented at the AUA North Central Section Meeting, November 1996

OTHER RESEARCH

Fertility update on nerve sparing RPLND in clinical stage I nonseminoma. Richard S. Foster, M.D., David C. Ragan, M.D., Richard Bihrle, M.D., Gregory Wahle, M.D., Benoit Hermans, M.D. and John P. Donohue, M.D.; Indiana University, Indianapolis, Indiana.
Presented by Dr. Foster at the AUA 93rd Annual Meeting, May 1998

International Study of patients with advanced non-seminomatous germ-cell tumors (NSGCT) and viable malignant cells at resection of residual masses. David C. Ragan, M.D., Craig Nichols, M.D., and Richard S. Foster, M.D.; Indiana University investigators. Investigator-coordinator, Karim Fizazi, M.D., Institut Gustave-Roussy, France.
Abstract presented by Dr. Fizazi, ASCO meeting 1999

CLINICAL RESEARCH TRIALS: SUB-INVESTIGATOR

Abbott 1994: **"Phase III BPH."**

Pfizer 1998: **"Phase III Impotence."**

Alza 1998-1999: **"Phase III OAB."**

Boehringer-Ingelheim 1998-2000: **"Phase III Study for Men with BPH."**

Boehringer-Ingelheim 2000 – 2001: **"Phase II Study for Men with Non-bacterial Prostatitis."**

NCI/Pharmacia 2000-Ongoing: **"Phase IIb-III Chemo Prevention for Bladder Tumor Recurrence in High-Risk Patients."**

Pfizer 2/2000-1/2002: **"Phase III Anticholinergic for Urge Incontinence."**

Pfizer 2000-3/2002: **"Open-label Extension for Urge Incontinence."**

Alza 2000-2001: **"Phase III Safety Study of Males with BPH."**

Barr 3/2001-5/2003: **"Phase III Study for Men with Vasomotor Hot Flashes as a Result of Being Treated with Hormone Manipulation Therapy for Prostate Cancer."**

Sample Acquisition for BLCA 3/2001: **"For the Testing in the Diagnosis of Bladder Cancer."**

Pfizer 5/2001: A1371027 **"A Phase II Multi-Center, Placebo Controlled, Pilot Study to Determine the Efficacy of Darifenacin in the Treatment of Nocturnal Symptoms."**

Pfizer 5/2001: A1371014 **"A Phase III, Multi-center, Open Label. Continuation Study of the Long Term Safety, Toleration, Compliance and Efficacy of Controlled Release Darifenacin in Subjects with Overactive Bladder."**

Boehringer-Ingelheim 6/2001-5/2002: **"Phase III Study of Alpha-Blocker for Treatment of AUR."**

Sanofi-Synthelabo 6/2001: **"A Long Term Efficacy and Safety of Alfuzosin 10 mg qd on the Risk of Acute Urinary Retention and the Need for Surgery in Patients with BPH. A Two-Year Randomized, Multi-Center, Double-Blind Parallel-Group, Placebo-Controlled Study."**

Pfizer 9/2001: A1371001 **"A Phase III, Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Controlled Release Darifenacin vs. Tolterodine in the Treatment of Subjects with Overactive Bladder."**

Auxillium 9/2001: TG-205 **"Evaluation of the Relationship between Genotype Expression Determined by DNA Analysis and Differences in Phenotypic Expression as Determined by Serum Testosterone Levels in Aging Males."**

Eli Lilly & Co. 2001-1/2002: **"Women with Stress Urinary Incontinence."**

Eli Lilly & Co. 2001-Ongoing: **"Open-Label Extension Protocol for Female Stress Urinary Incontinence."**

Alza 11/2001–6/2002: **"Phase IV OAB."**

Auxillium 3/2002: TG-202.00 **"An Evaluation of the Use of a Unique Testosterone Topical Gel Formulation in Males with a Testosterone level ≤ 300 ng/dL."**

Anthra Pharmaceuticals 2002: A9601 **"Intravesical AD 32 (N-Trifluoroacetyl Adriamycin-14-valerate) vs. No Adjunctive Therapy Immediately Following Transurethral Resection in Patients with Multiple Superficial (Ta and T1) Bladder Tumors."**

Pfizer 4/2001–5/2002: **"A Phase III Placebo-Controlled Pilot Study to Determine the Efficacy of Darifenacin in the Treatment of Nocturnal Symptoms of Overactive Bladder and Effects on the Quality of Sleep."**

Pfizer 9/2001–4/2002: **"Alpha-blocker for BPH."**

Auxillium 2001–2002: **"Phase III Study of Three Testosterone Products for Males with Hypogonadism."**

Hoffmann LaRoche 2001: NN 16378 **"A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Effects of a Partial Alpha 1A/1 L-Adrenoceptor Agonist (Ro115-1240) in Women with Stress Urinary Incontinence."**

Sanofi-Synthelabo 6/2001-7/2002: **"Alpha-blocker for treatment of AUR."**

Clinical Protocol 2002: **"Sample Acquisition for BLCA-4 Testing in the Diagnosis of Bladder Cancer."**

Pharmacia 4/2002-5/2003: **"A Double Blind, Placebo Controlled, Randomized Study, to Evaluate the Effect of an Anticholinergic on Nocturia in Patients with Symptoms of Overactive Bladder."**

Pfizer 6/2002: A2841018 **"A Multi-Center, Double-Blind, Double-Dummy, Randomized, Placebo and Tamsulosin Controlled Parallel Group Study to Assess the Efficacy and Safety of UK-338,003 in Subjects with Lower Urinary Tract Symptoms Due to Benign Prostate Obstruction."**

Sanofi-Synthelabo 4/2002–9/2002: EFC-4428 **"A Double-Blind, Randomized, Parallel Group Study of Alfuzosin 10 mg qd vs. Placebo in the Management of Acute Urinary Retention in Patients with a First Episode Due to BPH."**

Schwarz Biosciences 10/2002: SP668A **"A Phase II, Parallel Group, Stratified, Randomized, Double Blind, Placebo-Controlled Trial to Investigate the Efficacy and Safety of Three Different Dosages of Sustained Release Fesoterodine in Subject with Overactive Bladder Showing Either Involuntary Detrusor Contractions or Normal Findings During the Baseline Urodynamic Assessment."**

Novartis 2002: **"A 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Multi-Center Study to Evaluate the Efficacy of Darifenacin 15 mg qd on Increase in Warning Time, the Time from First Sensation of Urgency to Voiding, in Patients with OAB."**

Auxillium 2002: TG-203.01 **"An Open Label Use of a Unique Testosterone Topical Gel Formulation in Males with an Original Baseline Testosterone Level ≤ 300 ng/dL."**

GlaxoSmithKline 10/2003: ARI30019 **"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Oral Dutasteride (3.5mg) Administered Once Weekly to Placebo Administered Once Weekly for a 12 Month Period in Subjects with BPH."**

Pharmatech 3/2004: **"Protocol PUI-02809."**

Novartis Pharmaceuticals 2002: 03-034 US05 **"A Double-Blind, Placebo-Controlled Study of the Effect of Zoledronic Acid on Bone Mineral Density in Men Receiving Androgen-37)."**

Alza 8/2003: **"Deprivation Therapy for Prostate Cancer Phase IIIb Study of an Oral Heparin-Based Compound for the Treatment of Interstitial Cystitis."**

Eli Lilly 7/2003: **"Open-label Study of a PDE5 Inhibitor for the Treatment of ED Administered 'On Demand' in Men with Diabetes, HTN, and Other Special Populations"** exceeded enrollment goal.

GlaxoSmithKline 4/2003–Ongoing: Phase III(b) **"Study to Evaluate a 5a-reductase Inhibitor in the Prevention of PCA in Men at High Risk."**

GTX 9/2003-Ongoing: **"A Phase III Study of a Selective Estrogen Receptor Modulator in the Prevention of Osteoporosis in Men on Androgen Deprivation Therapy for Prostate Cancer."**

Novartis: 3/2003: **"Late Phase Study to Evaluate the Use of a Bisphosphonate for the Prevention of Osteoporosis in Men on Androgen Deprivation Therapy for PCA."**

Alza 6/2004: **"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of Elmiron for the Treatment of Interstitial Cystitis."**

Eli Lilly 6/2004: H6D-MC-LVFN(b) **"An Open Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered "On Demand" to Men of Various Populations with Erectile Dysfunction."**

Pharmatech 7/2004: **"Trelstar Study for Advanced Prostate Cancer."**

Novartis Pharmaceuticals 1/2005: 03-034 US05 **"A Double-Blind, Placebo-Controlled Study of the Effect of Zoledronic Acid on Bone Mineral Density in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer."**

Yamanouchi Pharma America 2/2005: **"An Open Label Study of the Efficacy and Safety of 5 and 10mg Vesicare (solifenacin succinate) in Patients with Overactive Bladder Symptoms."**

GlaxoSmithKline 5/2005: VAR102108/BAY38-9456/11575 **"Vardenafil 10mg Administered for 4 Weeks in a Fixed-Dose Regimen Compared to Placebo in Males with ED."**

Roche 7/2005: NU18191 **"Evaluation of Patients Who Completed More Than 180 Days of Active Treatment with Ro 115-1240."**

Duramed 4/2005: DR-PCA-201 **"A phase II, Randomized, Multi-Center, Placebo Controlled, Double-Blind, Dose-Ranging Clinical Trial To Study the Efficacy and Safety of 5mg,15mg, or 25mg/day CyPat (Cyproterone Acetate) for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients."**

Ortho-McNeil 9/2005: **"A Multi-Center, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 MG Once Daily for Five Days vs. Ciprofloxacin HCL 500 MG Twice Daily for Ten Days in the Treatment of Complicated UTI or Acute Uncomplicated Pyelonephritis (CAPSS-349)."**

GTX Pharmaceuticals 10/2005: G300104 **"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of Toremifene Citrate for the Prevention of Prostate Cancer in Men with High Grade PIN."**

MediciNova 9/2005: MN-001-CL-002 Phase II **"A Randomized Double Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients with Interstitial Cystitis."**

Novartis 5/2005: **"A 12-Week, Randomized, Open-Label, Parallel-Group, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Enablex (Darifenacin) (with Voluntary Up-Titration from 7.5 mg qd to15mg qd at 8 Weeks) Alone or in Combination with Behavioral Modification Program for Symptoms of Overactive Bladder."**

Pfizer Protocol 1/2005: A6061023 **"A Phase 2, 8-week Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel, Group Study Evaluating the Efficacy, Tolerability and Safety or (S.S)-Reboxetine (ONU-165442G) for Stress Urinary Incontinence in Women."**

Pfizer 10/2005: A6121146 **"A Multi-Center, Multiphase, Single Arm, Open Label, Study to Evaluate the Effects of Tolterodine ER In Conjunction with Behavioral Intervention on Subject Satisfaction and Overactive Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency) In Overactive Bladder Subjects, Who Were Dissatisfied With Their Most Recent Antimuscarinic OAB Medication Therapy."**

Watson Pharmaceuticals 5/2005: SIO4009 **"A Multi-Center Double-Blind Placebo Controlled Evaluation of the Safety of Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia."**

Watson Pharmaceuticals 5/2005: SIO4011 **"A Multi-Center Open-Label Evaluation of the Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH."**

Amgen 2/2005: 2000050147 **"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastases-Free Survival in Men with Hormone-Refractory Prostate Cancer."**

GlaxoSmithKline 2/2005: VAR102108/BAY38-9456/11575 **"A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection Following Vardenafil (10mg) Administered for 4 weeks in a Fixed-Dose Regimen Compared to Placebo in Males with ED."**

Eli Lilly 5/2005: FIJ-US-SBCD **"Evaluation of Efficacy and Safety of Duloxetine HCI in Women of Different Demographic Characteristics and Comorbidities with Stress UI."**

GlaxoSmithKline 10/2005: NKB-105022 **"A 12-Week Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Forced Titration, Proof of Concept Study to Assess the Efficacy, Safety and Tolerability and the Pharmacokinetic Profile of 60 mg vs. 120 mg of GW6799769 (GW679769) Administered Once Daily vs. Placebo in Women with Overactive Bladder."**

Astellas 4/2006: 905-UC-008 **"To Evaluate the Safety, Tolerability and Efficacy of Solifenacin Succinate (Vesicare) 5mg in Combination with Tamsulosin HCL (Flomax) for the Treatment of Residual Overactive Bladder Symptoms in Men Who are Treated with Flomax 0.4 mg for 4 Weeks."**

GlaxoSmithKline 5/2006: LEV106718 **"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-Dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects with Erectile Dysfunction and Dyslipidemia."**

Novartis 6/2006: CDAR328A2404 **"A 12-Week, Open-Label, Non-Randomized, Multi-Center Study to Evaluate the Patient's Perception of Outcome After Treatment with Darifenacin in Overactive Bladder Patients Dissatisfied with Prior Anticholinergic Therapy."**

GlaxoSmithKline 6/2006: AVO105948 **"A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who are Candidates for or Undergoing Expectant Management."**

Amgen 8/2006: 2005103 **"A Randomized, Double-Blind, Multi-Center Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer."**

Pfizer 2/2007: A6121146 **"A Multi-Center, Multiphase, Single-Arm, Open-Label, Study To Evaluate the Effects of Tolterodine ER in Conjunction with Behavioral Intervention on Subject Satisfaction and Overactive Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency) In Overactive Bladder Subjects Who Were Dissatisfied with Their Most Recent Antimuscarinic OAB Medication Therapy."**

Indevous 8/2007: **"A Two-Arm, Open-Label Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750mg and 1000mg Testosterone Undeconoate in Hypogonadal Men."**

Astellas 4/2007: 905-UD-008 **"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Safety and Efficacy, Phase 4 Study of Vesicare (Solifenacin Succinate) or Placebo in Combination with Tamsulosin HCL for the Treatment of Residual OAB Symptoms."**

Novartis 6/2007: **"A Twelve-Week, Open-Label, Non-Randomized, Multi-Center Study to Evaluate the Patient's Perception of Outcome After Treatment with Darifenacin in Overactive Bladder Patients Dissatisfied with Previous Anticholinergic Therapy."**

GlaxoSmithKline 10/2007: AVO105943 **"A Randomized Double-Blind Parallel Group Study Comparing Casodex 50 mg Plus Casodex 50 mg Placebo plus Dutasteride 3.5mg Administered for 18 Months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase."**

Astellas 11/2007: 905-UC-010 **"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-Center Study of Vesicare (Solifenacin Succinate) in OAB Subjects to Evaluate Symptom Bother and Health Related Quality of Life."**

Astellas 11/2007: YM178 **"A Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects with LUTS."**

TheraVita 9/2007: THVD-101 **"A Combination of an Antimuscarinic and Muscarinic Agonist vs. an Antimuscarinic Agent, Alone in Subjects with OAB."**

Spectrum 9/2007: SPI-611 "**A Multi-Center, Randomized Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin as a surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer."**

Pfizer 10/2007: A0001009 **"A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fesoterodine as an "Add-On" Therapy in Men with Persistent Overactive Bladder Symptoms Under Monotherapy of Alpha Blocker for Lower Urinary Tract Symptoms."**

Sanofi-Aventis 3/2008: DRI6271 **"A Placebo Controlled Randomized 12-Week Dose-Ranging, Double-Blind Study vs. Placebo using Tolterodine as Study Calibrator to Evaluate Efficacy and Safety of SSR240600C in Women with Overactive Bladder.**"

Tap Pharmaceutical 12/2007: L-PC07-169 **"A Phase III, Multi-Center, Open-Label Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two-6-Month Leuprolide Formulations in Subjects with Prostatic Adenocarcinoma."**

Astellas 4/2007: 178-CL-047 **"A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-Center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder."**

Astellas 4/2007: 178-CL-049 **"A Long-Term Phase III Study to Assess Safety and Efficacy of Beta-3 Agonist YM178 After Treatment of Subjects with OAB Symptoms."**

Pfizer 4/2007: A0221014–1011 **"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Fesoterodine Flexible Dose Regimen in Patients with Overactive Bladder."**

Pfizer 2/2008: A6061023 **"A Phase 2, 8-Week Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel, Group Study Evaluating the Efficacy, Tolerability and Safety or (S,S)-Reboxetine (ONU-165442G) for Stress Incontinence in Women.**"

Pfizer 2/2008: DRI6271 **"A Placebo Controlled Randomized, 12-week, Dose-Ranging, Double-Blind Study vs. Placebo, Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women with Overactive Bladder, Including Urge Urinary Incontinence."**

Argos Pharmaceuticals 2008: AGS-003-006 **"A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib."**

Merck 2009: 002-001 **"A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients with Selected Solid Tumors."**

Watson 2009: SIO8001 **"A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects with Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome."**

Ferring 2009: FE 200486 CS37 **"A Randomized, Controlled, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in Patients with Carcinoma of the Prostate with Biochemical Failure after Localized Therapy."**

Ferring 2009: FE 200486 CS35 **"An Open-Label, Multi-Center, Randomized, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy."**

Astellas 2009: 178-CL-074 2009 **"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder."**

Watson 2009: URO8004 **"A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Urocyst Compared to Inactive Vehicle Control in Subjects with Interstitial Cystitis/Painful Bladder Syndrome."**

Ferring 2010: 200486 CS36 **"A Dose Finding, Multi-Center, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial to Investigate Efficacy and Safety of Degarelix in Men with Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia."**

Warner Chilcott 2010: PR 01209 **"A Randomized Placebo-controlled, Double-Blind, Parallel Design Phase 3 Study to Assess the Safety and Efficacy of WC3043 Tablets in Male Subjects with Erectile Dysfunction."**

Warner Chilcott 2010: PR01409 **"An Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of WC3043 Tablets in Male Subjects with Erectile Dysfunction."**

Predictive Bioscience 2010: PR-001 **"Hematuria Evaluation Trial Device Trial."**

Predictive Bioscience 2010: PR-002 **"Hematuria Evaluation Trial Device Trial."**

Serenity Pharmaceuticals 2010: **"A Phase III Randomized, Double Blind, Placebo Control, Multi-Center Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients with Nocturia."**

RTOG 2010: 0621 **"Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy."**

Amgen 2010: 20080560 **"A Double-blind, Placebo-Controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-Metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy."**

Nymox 3/2010: **"Phase III Multi-Center, Prospective, Randomized, Parallel-Group, Placebo Controlled, Double-Blind, Clinical Evaluation of NX-12-07 for the Treatment of BPH."**

Ausio Pharmaceuticals 2010: **" A Randomized, Double-Blind, Multi-Center, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4-Weeks Treatment with (AUS 131) in Subjects with BPH."**

Urovalve 5/2010: **"Assessment of the Surinate® Bladder Management System for Urinary Retention in Men."**

Auxillium 10/2010: AUX-CC-804 **"A Phase III, Double-Blind, Randomized, Placebo Controlled, Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle, for Up to Four Treatment Cycles, in Men with Peyronie's Disease."**

Omeros Corporation 6/2010: **"A Double-Blind, Placebo Controlled, Concentration Escalating, Pharmacokinetic Study, Evaluating the Systemic Absorption, Safety and Efficacy of (OMS 201) in Subjects Undergoing Ureteroscopic Treatment of Ureteral or Renal Collecting System Located Stones."**

Discovery Health 5/2010: **"A Preliminary Validation of a Four Gene Signature Urine Test for the Early Detection of Prostate Cancer."**

Takeda Global Research and Development 1/2011: **"A Multi-Center, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase II Study to Evaluate Febuxostat in Medical Management of Subjects with Hyperuricosuria and Calcium Oxalate Stones."**

AstraZeneca 9/2010: **"A Phase III, Randomized, Double-Blind Study, to Assess the Efficacy and Safety of Once Daily Administered SD 4054 10 mg in Non-Metastatic, Hormone- Resistant Prostate Cancer Patients."**

Pfizer 11/2010: **"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy and Safety of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder."**

Astellas 1/2011: **"A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer."**

Ferring 1/2011: FE 200486 CS35A **"An Open-Label, Multi-Center, Extension Trial, Evaluating the Long-Term, Progression-Free Survival, of Degarelix or Goserelin Three Month Dosing Regimens in Patients with Prostate Cancer, Requiring Androgen Deprivation Therapy."**

RTOG 534 1/2011: **"A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy."**

RTOG 815 1/2011: **"A Phase III Prospective Randomized Trial Of Dose-Escalated Radiotherapy With Or Without Short-Term Androgen Deprivation Therapy For Patients With Intermediate-Risk Prostate Cancer."**

Centocor Ortho Biotech 2/2011: **"A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease."**

Nymox 2/2011: **"Phase 3 Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Clinical Evaluation of NX-1207 for the Treatment of BPH."**

Spectrum Pharmaceutical 5/2011: **"An International, Multi-Center, Open Label, Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix versus Goserelin Depot (Zoladex®) in Men with Prostate Cancer."**

SWOG 5/2011: **"A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer."**

University of California at San Francisco 6/2011: **"95982: Cancer of the Prostate Strategic Urologic Research Endeavor."**

Dendreon Corporation 7/2011: **"A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen after Primary Therapy."**

Endo Pharmaceutical 7/2011: **"A Phase 3B, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Maintenance Therapy with Valrubicin versus no Maintenance, in Subjects Treated with Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder."**

Dendreon Corporation 8/2011: **"A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer."**

Nymox 8/2011: **"Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: 1-7 Years Apart."**

Spectrum Pharmaceutical 10/2011: **"A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone versus Placebo in Patients with Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)."**

Dendreon Corporation 10/2011: **"A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer."**

University of California at San Francisco 6/2011: **"Cancer of the Prostate Strategic Urologic Research Endeavor (CaPsure)."**

Dendreon Corporation 8/2011: **"A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 As Adjuvant Therapy In Subjects With High Risk HER2+ Urothelial Carcinoma."**

Endo Pharmaceuticals 12/2011: **"A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate The Efficacy And Safety Of EN3348 (MCC) As Compared With Mitomycin C In The Intravesical Treatment Of Subjects With BCG Recurrent Or Refractory Non-Muscle Invasive Bladder Cancer."**

Astellas 5/2012: **"A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-Center Study To Assess Efficacy And Safety Of Continence Of Subjects After Robotic Assisted Radical Prostatectomy."**

Endo Pharmaceuticals 6/2012: **"Safety and Pharmacokinetics of ODM-201 In Patients With Castrate Resistant Prostate Cancer: Open, Non-Randomized, Uncontrolled, Multicenter, Multiple Dose Escalation Study With A Randomized Phase II Expansion Component."**

Nymox 6/2012: **"Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety And Efficacy Evaluation Of Injection Of NX-1207 For The Treatment Of Low Risk, Localized (T1c) Prostate Cancer."**

Myriad Genetic Laboratories, Inc. 7/2012: **"Assessment of a cell cycle gene expression assay in biopsies from patients with newly-diagnosed prostate adenocarcinoma."**

Endo Pharmaceuticals 7/2012: ARADES EXTENSION **"Safety and Tolerability of ODM-201 in Patients with Castrate Resistant Prostate Cancer: Open, Non-Randomized, Uncontrolled, Multicenter, Extension Study to Study 3104001/EN3386-202."**

Medivation 8/2012: **"STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men with Prostate Cancer who have Failed Primary Androgen Deprivation Therapy."**

Auxilium 8/2012: **"A Phase 3, Open-Label Study of the Safety and Effectiveness of AA4500 Administered Twice per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men with Peyronie's Disease."**

BNIT 8/2012: **"A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer."**

Eli Lilly 9/2012: **"A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% on Symptoms of Ejaculatory Dysfunction in Men with Testosterone Deficiency."**

Argos 11/2012: **"An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)."**

Augmenix 12/2012: AGX-11-001-US **"Evaluation of SpaceOAR™ System when used to Create Space Between the Rectum and Prostate in Men Undergoing Image Guided–Intensity Modulated Radiation Therapy (IG–IMRT) for Localized Stage T1–T2 Prostate Cancer: A Randomized, Multicenter, Parallel Arm Controlled Clinical Study."**

Dendreon 12/2012: P12-1 **"A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients with Castration-Resistant Prostate Cancer."**

Dendreon 12/2012: P12-2 **"A Randomized, Open-label, Phase 2 Study of Sipuleucel-T, With Concurrent Versus Sequential Administration of Enzalutamide in Men with Metastatic Castrate Resistant Prostate Cancer."**

FKD 12/2012: **"A Phase II, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects with High Grade, BCG Refractory, Relapsed or Resistant Non-Muscle Invasive Bladder Cancer (NMIBC)."**

Heat 12/2012: HS410-**101 "A Phase 1/2a, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT) and Received Prior Treatment with Induction Bacillus Calmette–Guérin (BCG)."**

OPKO 12/2012: **"The OPKO Diagnostics 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy."**

Auxilium 1/2013: UBC-A13183 **"Evaluating the Reproducibility of the Peyronie's Disease Questionnaire (PDQ)."**

RTOG 1/2013: 926 **"A Phase II Protocol For Patients With Stage T1 Bladder Cancer To Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Cisplatin Chemotherapy Following A Thorough Transurethral Surgical Re-Staging."**

Amgen 2/2013: 20101102 **"Osteonecrosis of the Jaw (ONJ) Case Registry."**

Dendreon 3/2013: P11-4 **"Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T (PRIME)."**

Telormedix: 5/2013: **"Phase II Pilot Study with TMX-101 in Patients with Carcinoma In Situ (CIS) Bladder Cancer."**

Aquinox Pharmaceuticals Inc. 6/2013: AQX-1125 **"A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-Domain-Containing Inositol 5' Phosphatase [SHIP1] Pathway."**

Neogenomics Laboratories 07/2013: **"Validation of an SVM Derived, Four-gene Signature Test in Blood and Urine for the Early Detection of Prostate Cancer."**

Warner Chilcott 8/2013 **"A study to assess the Safety and Efficacy of Udenafil in Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)."**

Evidera 9/2013: **"Qualitative Research on Patients Experience of Androgen Deprivation Therapy ADT."**

Astellas 12/2013: Synergy 178-CL-101 **"A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder."**

Sequoia 1/2014: SQ-SH171 **"Phase 1 Dose-Escalation Study of the Safety and Immunogenicity of FimH, an Escherichia Coli Pilus Vaccine, With and Without Adjuvant, in Healthy Adult Women with and without a history of Recurrent Urinary Tract Infections."**

Sophiris 1/2014: PRX302-3-01 **"A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of a Single Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (The PLUS 1 Trial)."**

Evidera 2/2014: A2-8796-007 **"Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q)."**

Myriad 2/2014: **"A Feasibility Study to Determine Whether Bladder Cancer can be Detected by Mutational Screening of DNA Markers in Urine."**

Pfizer 02/2014: A4061070 **"Metastatic Renal Cell Cancer Registry (MaRCC)."**

Genomic Health Inc. 4/2014: Oncotype DX 09-023 **"A Prospective Multicenter Observational Trial to Assess Persistence on Active Surveillance When Using the Oncotype DX Prostate Cancer Assay."**

Minomic International Ltd 4/2014: "**MiStat™ ELISA Pilot Study (Pilot Study) for Prostate Cancer."**

PASCUAL (Prostate Assay Specific Clinical Utility at Launch Study) 4/2014: **"A Randomized, Controlled Prospective Study to Track the Clinical Utility of an Epigenetic Assay, ConfirmMDx® for Prostate Cancer, in U.S. Urologic Practices for Histologically Cancer-Negative Patient Management."**

Takeda 4/2014: C27002 **"A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer."**

Astellas 05/2014: 178-CL-101/102 SYNERGY **"A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-Center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder."**

Takeda 5/2014: C27003 **"A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)."**

Auxilium 6/2014: 810 **"Long-Term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated with aa4500 for Peyronie's Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804, AND AUX-CC-806."**

GenomeDx Biosciences Decipher 7/2014: **"Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population."**

Janssen/SPARTAN 9/2014: ARN-509 **"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer."**

Genomic Health Inc. 9/2014: 14-001 **"Genomic Markers In Transitional Cell Cancer Of The Bladder, Renal Pelvis And Ureter: Sample Acquisition For Methods Development And Discovery."**

Mundipharma Research Limited 10/2014: **"A Phase 2 Randomized, Double-Blind, Placebo Controlled, Study of MR901 in Patients with Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)."**

Medivation Inc, EMBARK 12/2014: **"A Phase Three, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing after Definitive Therapy."**

Janssen /Aragon Pharmaceuticals 2/2015: METS PCR3001 **"A Phase 3 Randomized, Placebo-Controlled Double-Blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC)."**

Astellas TRUMPET 03/2015: ONC-MA-1004 **"A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States."**

University of Colorado Anschutz Medical Campus CU Optics 3/2015: **"Performance Evaluation of The Claricore Optical Biopsy System Designed by Precision Biopsy for Prostate Cancer Diagnosis."**

Orion Pharma 3/2015: 3104007 ARAMIS **"A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase 3, Efficacy and Safety Study of Odm-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer."**

Bayer 5/2015: ODM17777 **"A Randomized, Double-Blind, Placebo Controlled Phase III Study of ODM-201 Versus Placebo in Combination with Standard Therapy (Androgen Deprivation Therapy (ADT) with or without a Docetaxel Containing Chemotherapy Regimen) for Patients with Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer (mCSPC)."**

Janssen/Aragon Pharmaceuticals 6/2015: PCR 3002 **"A Phase 3 Randomized, Placebo-Controlled, Double-blind Study of JNJ-56021927 plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)."**

Tokai Pharmaceuticals 8/2015: Armor3-Sv **"A Phase 3, Randomized, Open Label, Multicenter, Controlled Study of Galeterone Compared To Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 Mrna (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)."**

NeoGenomics Laboratories 8/2015: 6 **"Predicting Prostatectomy Results using Blood and Urine Biomarkers."**

Bayer 9/2015: BAY88-823-15396 Radium **"A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Subjects with Bone Predominant Metastatic Castration-Resistant Prostate Cancer (CRPC)."**

Janssen/Aragon Pharmaceuticals 9/2015: PCR 3003 **"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy."**

Spectrum Pharmaceutical 9/2015: SPI-EOQ-13-305 **"A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing Transurethral Resection for Non-Muscle Invasive Bladder Cancer."**

Genomic Health 10/2015: 14-006 **"Clinical Validation of a Urine-Based Assay with Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-Muscle Invasive Bladder Cancer."**

Augmenix 10/2015: AGX-15-001 US **"Long Term Follow-up of Patients Who Had Previously Been Implanted With the SpaceOAR System and Unimplanted Controls Undergoing Image Guided - Intensity Modulated Radiation Therapy (IG-IMRT) for Prostate Cancer: A Non-Significant Risk Assessment."**

Genomic Health Confirm MDX 02/2016 **"A Prospective Study to Evaluate the Clinical Utility of the ConfirmMDx® for Prostate Cancer Assay for Men with Previous Histologically-Negative Prostate Biopsies".**

Ferring 2/2016 Degarelix, FE 200486 000108 ADT **"A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH antagonist) or Leuprolide (LHRH agonist)."**

Janssen REAAcT 3/2016 212082PCR4038, Phase 4 **"A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment with Enzalutamide or Abiraterone Acetate (with Prednisone) for Metastatic Castration - Resistant Prostate Cancer (mCRPC)."**

Eli lilly/Q2 solutions 3/2016: GU 115-6A-MC-CBBD **"A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer."**

Beckman Coulter 4/2016: PHI-HERO-01-15 **"A Prospective, Observational Study of the Clinical Decision Impact of the Prostate Health Index (phi) Test in a Urology Practice Setting."**

GenomeDx Biosciences 5/2016: GRID Decipher **"Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population."**

Amgen 6/2016 A.D.A.P.T. CUSP **Bone Health Registry – "Race, Bone Health and the Cardiometabolic Consequences of Androgen Deprivation Therapy for Prostate Cancer."**

Astellas 8/2016: 178-MA-1008 **"A Phase 4 Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)."**

Astellas 8/2016: 9785-MA-1010 **"A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)."**

Precision Med, Inc 8/2016: 6504 **"Collection of Blood, Urine and Tissue Samples from Patients with Solid Malignant Tumors."**

Precision Biopsy 8/2016: CIP-1010 **"Prospective, Multi-Center Study of the ClariCore™ Optical Biopsy System in Patients Undergoing TRUS-Guided Prostate Biopsy With or Without MR Fusion For Prostate Tissue Classification Algorithm Development."**

FKD 9/2016: rAd-IFN-CS-003 **"A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)."**

Janssen 10/2016: PCR2001 **"A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies."**

Cepheid 12/2016: Xpert Bladder Assay **"Clinical Evaluation of Xpert® Bladder Cancer Monitor For Monitoring the Recurrence of Bladder Cancer."**

OPKO 01/2017: Sangia tPSA **"A Clinical Study to Evaluate the Effectiveness of Circulating Total Prostate Specific Antigen (tPSA) as Measured by the Sangia tPSA Assay as an Aid in the Early Detection of Prostate Cancer (PCa)."**

Nucleix Ltd 03/2017: UC-EpiCheck-FDA-01 **"The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma A Multicenter, Prospective Blinded Pivotal Study."**

Hoffman LaRoche 04/2017: Genentech WO39210 **"A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis following Nephrectomy."**

Hoffman LaRoche 04/2017: Genentech WO29636 **"Open-Label, Multicenter, Randomized Study of Atezolizumab Versus Observation As Adjuvant Therapy In Patients With Pd-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy."**

Astellas 4/2017: 9785-CL-0123 Mole Strive Rollover **"A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study."**

Spectrum 05/2017: SPI-QAP-306 **"A Randomized, Multicenter, Two-Arm, Single-Dose, Double-Blind, Placebo-Controlled Phase 3 Study of Intravesical Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrethral Resection of Bladder Tumors in Patients with Low to Intermediate Risk Non-Muscle Invasive Bladder Cancer." (CONQUER)**

Myovant 5/2017: MVT-601-3201 HERO "**A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer."**

Bayer 10/2017: 17777 **"A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer."**

Minomic International Ltd 10/2017: **"MiCheck- 01 Prospective Prostate Cancer Study."**

Cato Research 11/2017: FP01C-17-001 Foresee Pharmaceuticals Co., Ltd. / **"An Open-Label, Single-Arm Study of the Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects with Prostate Cancer."**

Pfizer 11/2017: C3441021 **"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Talazoparib In Combination With Physician's Choice Of Enzalutamide Or Abiraterone Acetate/Prednisone In Metastatic Castration-Resistant Prostate Cancer With DNA Damage Repair Deficiencies."**

OPKO 05/2018: 20086-1 **"Sangia Total PSA Test Analytical Studies in Clinical Settings Protocol"**
Urogen 06/2018: TC-UT-03-P **"A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ (UGN-101) on Ablation of Upper Urinary Tract Urothelial Carcinoma."**

Siemens 06/2018: Siemens Multiplatform-201601.PRO **"Specimen Collection at Urology Practices for PSAII & PSAII Assays on ADVIA® Centaur Systems and Atellica IM Analyzers."**

Janssen 07/2018: 64091742PCR2002 **"A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic-Castration-Resistant Prostate Cancer."**

Veru 08/2018: V72203 **"Randomized, Double-Blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing Of VERU-944 After A Week Of Loading (Daily Dosing) With Placebo To Ameliorate The Vasomotor Symptoms Resulting From Androgen Deprivation Therapy In Men With Advanced Prostate Cancer (Pro00027622)."**

Dendreon 09/2018: P17-1 **"A Randomized Phase 3, Open-Label Trial Of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer."**

Merck 09/2018: MK-3475 **"A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy."**

Urogen 12/2018: TC-BC-12 **"A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemobalative Therapy in Patients with Low Grad (LG) Non-Muscle –Invasive Bladder Cancer (NMIBC) as Intermediate Risk of Recurrence."**

Vaxiion 05/2019: VX0116 **"Phase I Safety and Tolerability of Intravesical VAX014 for Installation in Subjects with Non-Muscle Invasive Bladder Cancer (NMIBC)."**

AstraZeneca 05/2019: D081SC00001 **"A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration Resistant Prostate Cancer (PROPEL)."**

Janssen 06/2019: PCR3011 "**A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy." (PROTEUS)**

Hinova 9/2019: HC-1119-CS-03 **"A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)."**

Genomic Health 12/2019: **09-060 "A real-world observational study to provide prospective information on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression after at least one line of androgen receptor-targeted therapy (ARTT) and the use of the Oncotype DX AR-V7 Nucleus Detect® assay in subsequent management."**

Epizyme 12/2019: EZH-1101 **"A Phase 1B/2 Open-Label Study Evaluating Tazemetostat in Combination with Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naïve Subjects with Metastatic Castration Resistant Prostate Cancer."**

BioExcel 1/2020: BXCL701-201: **"A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD 1)**

Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)."

QED Therapeutics, Inc. 4/2020: **"Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)."**

Bristol-Myers Squibb CA209.7DX 4/2020: **"A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX."**

Janssen 6/2020: BLC2003 **"A Randomized Phase 2 Study of Erdafitinib versus Investigator Choice of Intravesical Chemotherapy in Subject's who received Bacillus Guerin (BCG) and recurred with High-Risk Muscle Invasive Bladder Cancer (HR-NMIBC) and FGFR Mutations of Fusions."**

Bayer (17712 Roll-over Study) Orion 3104007 7/2020: 20321 **"An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies (Pro00043703)."**

Exelixis 8/2020: XL 184-315 **"A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs. Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration Resistant Prostate Cancer."**

Janssen 10/2020: **17000139BLC2001 (SunRise 1) "Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy."**

Janssen 10/2020: **17000139BLC3001 (SunRise 2) "A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination with Cetrelimab (JNJ-63723283) versus Concurrent Chemoradiotherapy in Patients with Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy."**

Janssen 12/2020: PCR2041: **"A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases."**

CUSP 12/2020: PC18-1005 (ESCALATE): **"A Phase III Randomized Study Comparing Enzalutamide or Darolutamide with Radium-223 vs Enzalutamide or Darolutamide with Placebo and the Effect upon Symptomatic Skeletal Event-Free Survival mCRPC Patients."**

Janssen 1/2021: **67652000PCR3002 (Amplitude)- "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)."**

Tavanta 2/2021: TAVT45C02**-"Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone acetate formulation in patients with metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)."**

Pfizer 2/2021**: B8011006 (CREST) "A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer."**

AstraZeneca 3/2021: **D361BC00001(CAPtello): "A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatments for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency."**

Bayer 9/2021**:** 20590 **DAROL: "Darolutamide Observational Study in nonmetastatic castration-resistant prostate cancer patients."**

Myovant 04/2023: **MVT-601-058 "A Multi-Center, Prospective, Observational Study of Patient Being Treated with ORGOVYX."**

Cleveland Dx 06/2023: **CDx2023-01B "A Prospective, Non-Randomized, Single-Blind, Multi-Site Study for SupplementaL Clinical Validation of the IsoPSA Assay."**